ChromaDex Announces Issuance of Additional New U.S. Continuation Patent, Further Protecting Future Innovations
March 16 2022 - 6:31AM
Business Wire
A newly granted continuation patent provides
additional intellectual property protection for ChromaDex’s Niagen®
ingredient and other nicotinamide adenine dinucleotide (NAD)
precursors
ChromaDex Corp. (NASDAQ:CDXC) today announced that it was
granted an additional continuation patent, U.S. Patent No.
11,274,117, adding to its global patent portfolio surrounding
nicotinamide riboside (NR) and other nicotinamide adenine
dinucleotide (NAD) precursors. This newly granted continuation
patent reinforces U.S. Patent No. 11,242,364, which was just
granted to ChromaDex on February 8, 2022 (full press release here).
ChromaDex currently owns and licenses a robust patent portfolio of
over 40 granted patents relating to Niagen® (patented NR) and other
precursors of NAD, a molecule at the forefront of the burgeoning
healthy aging category. Niagen® is the sole active ingredient in
ChromaDex’s flagship product, Tru Niagen®.
“Awareness around the importance of NAD in aging continues to
grow, and the market for novel NAD precursors, like NR, continues
to expand,” said Aron Erickson, ChromaDex Vice President of
Research & Development. “This patent adds further protection of
a novel method of making NR chloride to our portfolio. I am honored
to have led a team on the development of this important
patent.”
This new patent, U.S. Patent No. 11,274,117, relates to a novel
method of making nicotinamide riboside (NR) chloride salt. Both
newly announced patents allow ChromaDex to protect the
manufacturing process of NR Chloride and other new NR salt forms,
which can be leveraged in future innovations. Like U.S. Patent No.
11,242,364, U.S. Patent No. 11,274,117 will expire Nov. 10,
2037.
U.S. Patent No. 11,274,117 is part of the patent family titled
“Efficient and Scalable Syntheses of Nicotinoyl Ribosides and
Reduced Nicotinoyl Ribosides, Modified Derivatives Thereof,
Phosphorylated Analogs Thereof, Adenylyl Dinucleotide Conjugates
Thereof, and Novel Crystalline Forms Thereof”.
For additional information on ChromaDex, please visit
www.chromadex.com.
About ChromaDex:
ChromaDex Corp. is a global bioscience company dedicated to
healthy aging. The ChromaDex team, which includes world-renowned
scientists, is pioneering research on nicotinamide adenine
dinucleotide (NAD+), levels of which decline with age. ChromaDex is
the innovator behind NAD+ precursor nicotinamide riboside (NR),
commercialized as the flagship ingredient Niagen®. Nicotinamide
riboside and other NAD+ precursors are protected by ChromaDex’s
patent portfolio. ChromaDex maintains a website at
www.chromadex.com to which ChromaDex regularly posts copies of its
press releases as well as additional and financial information
about the Company.
Forward-Looking Statements:
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended,
including statements related to ChromaDex’s intellectual property
position and protection provided for new salt forms which can be
leveraged in future innovations. Statements that are not a
description of historical facts constitute forward-looking
statements and may often, but not always, be identified by the use
of such words as "expects," "anticipates," "intends," "estimates,"
"plans," "potential," "possible," "probable," "believes," "seeks,"
"may," "will," "should," "could" or the negative of such terms or
other similar expressions. More detailed information about
ChromaDex and the risk factors that may affect the realization of
forward-looking statements is set forth in ChromaDex's Annual
Report on Form 10-K for the fiscal year ended December 31, 2020,
ChromaDex's Quarterly Reports on Form 10-Q and other filings
submitted by ChromaDex to the SEC, copies of which may be obtained
from the SEC's website at www.sec.gov. Readers are cautioned not to
place undue reliance on these forward-looking statements, which
speak only as of the date hereof, and actual results may differ
materially from those suggested by these forward-looking
statements. All forward-looking statements are qualified in their
entirety by this cautionary statement and ChromaDex undertakes no
obligation to revise or update this release to reflect events or
circumstances after the date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220316005235/en/
ChromaDex Media Contact: Alex Worsham, Vice President of
Global Marketing & Communications 310-388-6706 ext. 689
alexw@chromadex.com
ChromaDex Investor Relations Contact: Brianna Gerber,
Vice President of Finance and Investor Relations 949-419-0288 ext.
127 briannag@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Jun 2024 to Jul 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Jul 2023 to Jul 2024